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Oral rehydration therapy for the treatment of acute
diarrhea has been acclaimed as one of the most important
therapeutic advances of the past century (1). The devel-
opment of oral rehydration solution (ORS) some 4 de-
cades ago was an immediate consequence of physiologic
studies of glucose-stimulated Na absorption in the small
intestine in humans and experimental animals. The
physiologic basis for ORS was the demonstration that
absorption and secretion are separate and distinct pro-
cesses in the intestine; cyclic nucleotides induce fluid
secretion without affecting glucose-stimulated Na ab-
sorption; and glucose enhances Na and fluid absorption
without modifying fluid secretion.
Oral rehydration therapy, using a relatively iso-
osmolar glucose-electrolyte solution with the addition of
a base (either bicarbonate or citrate), rapidly became
adapted throughout the developing world and was found
to reduce substantially the morbidity and mortality of
acute diarrhea in children, especially in those younger
than 5 years. The efficacy of the standard World Health
Organization (WHO)-ORS was based on the correction
of the dehydration and metabolic acidosis that occurs
during an episode of severe diarrhea, e.g., cholera. Un-
fortunately, WHO-ORS did not dramatically reduce stool
output (i.e., diarrhea), so during the next 20 years there
were multiple efforts to develop a “super” or “super-
super” (i.e., an improved ORS that would reduce diar-
rhea, in addition to its correction of dehydration and
metabolic acidosis).
Most of these efforts focused on the inclusion of dif-
ferent dietary substrates and were directed to stimulation
of Na absorption in the small intestine. Thus, several
studies evaluated amino acids without evidence of dra-
matic improvement compared with the gold standard of
WHO-ORS. Additional studies with food-based sources
of glucose (e.g., rice-based, cereal-based ORS) demon-
strated improved efficacy in the treatment of acute diar-
rhea (2). In general, these newly developed ORSs were
found to be most effective in adults with cholera but
substantially less so in children with diarrheal episodes
secondary to noncholera etiologies. These different food-
based ORSs all contained polymers that, following their
digestion by pancreatic and intestinal enzymes, resulted
in glucose production. As a consequence, these solutions
frequently were used with a reduced osmolality. Subse-
quent studies proposed that the primary efficacy of these
food-based solutions was their hypo-osmolar composi-
tion (3). All of these solutions are generally believed to
result in enhanced small intestinal fluid absorption.
Nonetheless, efforts continued to develop other im-
proved ORSs. These more recent approaches have
sought to use short-chain fatty acid (SCFA)-stimulated
Na absorption in the large intestine as an adjunct to
glucose-stimulated Na absorption in the small intestine
(4). SCFAs are not normal constituents of the diet but
are produced primarily in the colon by colonic bacteria
from nonabsorbed carbohydrate (5). This approach with
SCFAs was based on the unexpected observation that
cholera toxin and cyclic nucleotides did not inhibit
SCFA-stimulated Na absorption from the colon either in
vivo or in vitro (6,7). These experimental observations
were surprising because the mechanism of SCFA-
stimulated Na-Cl absorption includes a luminal mem-
brane Na-H exchange (NHE) that was coupled to SCFA
uptake via luminal membrane SCFA-HCO3 and Cl-
SCFA exchanges (8). Previous studies had established
that intestinal Na-Cl absorption represented the coupling
of Na-H and Cl-HCO3 exchanges in the luminal mem-
brane and that cyclic nucleotides inhibit small intestinal
Na-Cl absorption as a result of their inhibition of Na-H
exchange. Thus, it appeared that cyclic nucleotides re-
duced HCO3-dependent Na-Cl absorption by virtue of
their inhibition of Na-H exchange but did not affect
Na-H exchange when the latter is linked to SCFA-
stimulation of Na-Cl absorption.Supported in part by Wellcome Trust.
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This apparent paradox was resolved in studies of the
effect of cyclic AMP on the two different Na-H ex-
change isoforms (NHE-2 and NHE-3) in the luminal
membrane of both the small and large intestine (9).
These experiments demonstrated that HCO3-dependent
Na absorption was linked to NHE-3 isoform but not to
NHE-2 isoform. In contrast, SCFA-dependent Na ab-
sorption was coupled to both NHE-3 and NHE-2 iso-
forms. The final piece of the initial paradox was the
demonstration that cyclic AMP inhibited NHE-3 isoform
but also increased the activity of NHE-2 isoform. Thus,
cAMP inhibits HCO3-dependent Na-Cl absorption be-
cause it down-regulates NHE-3 isoform, which is the
only NHE isoform that mediates HCO3-dependent Na-Cl
absorption. In contrast, butyrate-dependent Na-Cl ab-
sorption is not altered by cAMP because cAMP up-
regulates NHE-2 isoform which, like NHE-3 isoform,
can mediate butyrate-dependent Na-Cl absorption.
These observations provided the basis for the proposal
that ORS plus a poorly digested starch (i.e., one that
was relatively resistant to amylase digestion), would re-
sult in increased delivery of carbohydrate to the colon;
that in turn would result in increased production of
SCFA; the latter would enhance Na and fluid absorption
from the colon, despite increased amounts of cyclic
nucleotides in colonic epithelial cells. Thus, this specu-
lation raised the possibility that the use of amylase-
resistant starch (RS) would capitalize on the absorptive
capacity of the large intestine for fluid and electrolytes to
augment absorption from the small intestine after inges-
tion of WHO-ORS.
To test this novel hypothesis that RS when added to
ORS would result in enhanced colonic fluid absorption
and, as a consequence, in reduced stool output, it was
first necessary to demonstrate that RS was fermented to
SCFAs by the bacteria in diarrheal stool (i.e., in different
diarrheal illnesses there had not been a change in the
fecal flora to one with a decreased fermentation capac-
ity). Studies at Christian Medical College in Vellore,
India, confirmed that SCFAs were produced when stool
from patients with cholera was incubated in vitro with
RS (10). This observation provided the basis for proceed-
ing with a double-blind, randomized clinical trial of adult
patients with cholera who were treated with RS-ORS,
rice flour-ORS, or WHO-ORS (4). The RS used in this
study was high-amylose maize starch produced from
Australian maize. Ramakrishna et al. (4) demonstrated
that patients who received RS-ORS had both a signifi-
cantly reduced stool output and a shorter time to the first
formed stool when compared with the other two treat-
ment groups in this study. Of potential importance was
that the first decrease in stool output was observed in the
second 12-hour stool collection, with greater decreases
seen in the subsequent two 12-hour stool collections.
These observations provided evidence that RS-ORS
might be the next super ORS, but additional observations
would be required before the search for a new ORS was
considered successful. These experimental results raised
the additional possibility that at least part of the effec-
tiveness of meal-based or cereal-based ORS might be
related to the fermentation of nondigested food carbohy-
drates to SCFAs in the colon, and not solely a result of
their hypo-osmolality. Additional studies are required
before this alternate suggestion will be widely accepted.
To assess whether ORS containing nondigestible car-
bohydrate (RS equivalent) is better than standard ORS in
children, Hoekstra et al. (11) recently completed a mul-
ticenter controlled trial in children with acute noncholera
diarrhea. The results of this study, reported in this issue
of the Journal, did not demonstrate a superiority for RS-
equivalent ORS but observed that there was no differ-
ence between the intervention and the control group with
regard to the two primary end points: stool output and
time to the first formed stool.
Does this end the trail of another potential candidate
(i.e., RS-ORS) for the super ORS? We suspect not be-
cause there were major differences in the study designs
of these two randomized controlled studies of RS-ORS:
(1) different RS formulations; (2) different RS concen-
trations; (3) varying degrees of severity of diarrhea; (4)
different ages of the subjects; and (5) different etiologies
of their diarrhea.
Different formulations of RS were used in these two
studies (4,11). In contrast to the high amylase maize
starch (HAMS) used in the Indian study, the pediatric
study conducted by members of the ESPGHAN used as
their RS equivalent a mixture of nondigestible carbohy-
drates (NDC) whose four major constituents were soy
polysaccharide, inulin, gum arabic, and fructo-oligosac-
charides. The hypothesis upon which RS-ORS is based is
that the colonic bacteria metabolize RS to SCFAs, which
enhance colonic fluid and Na-Cl absorption. The choice
of RS is not inconsequential because different formula-
tions of RS may not be fermented to SCFAs (especially
butyrate) as effectively as others. Starch is fermented
rapidly and preferentially to butyrate, compared with
other nondigestible carbohydrates, and butyrate stimu-
lates colonic Na absorption to a greater extent than do
other SCFAs (e.g., propionate, acetate) (12).
The concentration of the nondigestible carbohydrate
used may be critical to the resulting concentration of
SCFAs established in the colonic lumen by fermentation.
The current multicenter study used NDC concentrations
of 1 g/100 mL of ORS, which is substantially lower than
the RS concentration of 5 g/100 mL used in the study by
Ramakrishna et al. Rabbani et al. (13) used a concentra-
tion of green banana of 25 g/100 mL or pectin at 1.5
g/100 mL, which both were efficacious in reducing di-
arrhea in children with persistent diarrhea. Alam et al.
(14) used partially hydrolyzed guar gum as an NDC in a
dose of 2 g/100 mL. The current study was the only one
to use a mixture of carbohydrates, unlike the others, in
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which the source of NDC usually was a single defined
component (i.e., starch, pectin, or guar gum).
Also critical is whether the bacterial flora of the chil-
dren in the current study was capable of metabolizing the
NDC used in this study (or any RS) to SCFA. Ra-
makrishna et al. (10) established before the initiation of
their study that SCFAs were produced when the stool
from patients with cholera was incubated with HAMS.
Both the type of RS and the enteric flora of these subjects
are critical for SCFA production. The possibility exists
that (1) the enteric flora of boys younger than 3 years (the
study group in this trial) normally do not ferment all or
certain carbohydrates as well as that of adults; (2) the
enteric flora in these children was changed by their non-
cholera diarrhea such that the ability to produce SCFAs
was reduced; or (3) the particular source of RS used in
this study (NDC) was not metabolized to SCFA as ef-
fectively as HAMS. The studies of Rabbani et al. (13)
and Alam et al. (14), both using NDCs in children, dem-
onstrated evidence of a shortened duration of diarrhea in
their treatment group. The issue of whether SCFAs were
produced is not theoretical because Argenzio et al. (15)
found in a study of a transmissible gastroenteritis virus in
3-day-old and 3-week-old pigs that newly born pigs de-
veloped severe diarrhea whereas the older pigs had mini-
mal diarrhea as viral-induced jejunal fluid secretion was
compensated by colonic production of SCFAs. The
newly born pigs, in contrast to the 3-week-old pigs, did
not produce SCFAs because their colonic flora did not
contain the bacteria responsible for fermentation. Indeed,
in a recently concluded study in noncholera diarrhea in
children that was conducted at Christian Medical Col-
lege, we have noted that diarrhea is modestly but signifi-
cantly reduced in children treated with RS (i.e., HAMS-
ORS) compared with ORS alone, in addition to standard
rehydration therapy (unpublished observations).
Another important issue in the pediatric study was that
the diarrhea was relatively mild, so it might be impos-
sible to demonstrate improvement for any therapy com-
pared with the control group. This issue is similar to the
difficulty in establishing improved outcomes after acute
myocardial infarction without stratifying according to
complications (16). There also is concern with regard to
the different composition of the ORS that was used in the
two studies. The study of adults with cholera used WHO-
ORS, which is approximately iso-osmolar (318
mOsm/kg H2O), whereas the pediatric trial used a hypo-
osmolar ORS with an osmolarity of 250 mOsm/kg H2O
and a reduced [Na] of 60 mEq. Hypo-osmolar ORS re-
cently has been considered better than standard ORS.
Thus, because a control group treated with a hypo-
osmolar solution probably will have a better outcome
than one treated with WHO-ORS, a new therapy might
not demonstrate significant improvement when com-
pared with a hypo-osmolar control group.
In conclusion, the issue of the incorporation of
amylase-resistant starch in ORS has not been definitively
established one way or another, and additional studies
are required to establish the appropriate role of RS-ORS
in the therapy of acute diarrhea. Such studies must in-
clude observations in children without cholera and in
multiple age groups from a variety of locations through-
out the developing world. When these studies establish
the efficacy of RS-ORS, then RS-ORS will be ready for
prime time!
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